It has been reported that SPRC mitigated cognitive impairment and ultrastructural neuronal damage by inhibiting TNF-α, cyclooxygenase-2 (COX-2), ERK1/2, and NF-κB following Aβ25–35 injection [61]. The gene discussed is NFKB1; the disease is Cognitive impairment.